Lunai Bioworks Inc. is facing potential delisting from the Nasdaq Capital Market after receiving notice from Nasdaq that the company is not in compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5550(a)(2). The company's stock traded below this threshold for 30 consecutive business days, triggering the notice. Due to a 1-for-10 reverse stock split conducted within the past year, Lunai Bioworks is not eligible for a standard 180-day compliance period. The company has requested a hearing to appeal the delisting determination, which temporarily stays the suspension of its securities pending the outcome. If the appeal is unsuccessful or not filed by the deadline, Lunai Bioworks’ shares will be suspended from trading and officially delisted.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-000221), on February 12, 2026, and is solely responsible for the information contained therein.